I-uloric (febuxostat) yamukelwa yi-US FDA ngoFebhuwari 13, 2009. I-Uloric yindlela yokuqala yokwelapha entsha eminyakeni engama-40 ngeziguli ezine- hyperuricemia kanye ne-gout, ngokusho kwe-Takeda Pharmaceuticals North America, Inc.
I-uloric iyisidakamizwa esetshenziselwa ukuphathwa okungapheli kwe-hyperuricemia ku-gout. I-uloric yehlisa amazinga we-serum uric acid ngokuvimbela i-xanthine oxidase-i-enyzme enesibopho sokukhiqizwa kwe-uric acid.
I-Xanthine oxidase yehla i-hypoxanthine (etholakala enhlobonhlobo ye-purine) ku-xanthine, bese i-uric acid.
Iphathwe kanjani nge-Uloric?
Amanani okuvunyelwa oku-Uloric angama-40 mg no-80 mg okumele anikezwe kanye ngosuku. Uloric imithi yomlomo (ethathwe ngomlomo). Isilinganiso sokuqala sokuphakanyiswa kwe-Uloric singama-40 mg kanye ngosuku. Ukwenyuka kuya ku-80 mg kunconywa iziguli ezingafinyeleli i-serum uric acid engaphansi kuka-6 mg / dL ngemuva kwamasonto amabili kumthamo we-40 mg. I-uloric ingathathwa noma ngaphandle kokudla futhi ayikho izincomo ezivimbela ukusetshenziswa kwe-antacids. Akukho ukulungiswa kwesilinganiso okudingekayo ezigulini ezinomsoco ophansi noma olinganiselayo noma ukukhubazeka kwe-hepatic.
Ukusebenza ezimvivinyweni zemitholampilo
Ezilingo zomtholampilo, izinga eliphezulu le-Uloric litholakala ukuthi liphumelela kakhulu kune-placebo noma i-dose standard allopurinol - enye imithi esetshenziselwa ukwelapha i-hyperuricemia. Futhi, esilinganisweni sezinyanga ezingu-6 sesigaba III-iphesenti yeziguli zogciwane, ezanciphisa amazinga azo e-uric acid kumazinga afunayo ngaphansi kuka-6, ayephakeme kakhulu kulabo abathatha ama-80 mg kunelabo abathatha ama-40 mg we-Uloric.
Imiphumela emibi kanye nezixwayiso
I-uloric ayinconywa kubantu abane-hyperuricemia engavamile. I-uloric akufanele isetshenziswe abantu abasesiphathwe kakade nge- azathioprine (Imuran), mercaptopurine, ne-theophylline.
Ngokusekelwe kwizifundo ezintathu zokwelashwa ezingahleliwe, ezilawulwa yisibindi , ukungafaki kwesibindi , i-arthralgia, nokuqhaqhabalaza ukuphendula okubi kakhulu okubangelwa okungenani u-1% weziguli eziphathwe nge-Uloric futhi okungenani u-0.5% ngaphezulu kune-placebo.
Futhi, uma kuqhathaniswa ne-allopurinol, i-Uloric yayihlotshaniswa nesilinganiso esiphezulu sezehlakalo ze-cardiovascular thromboembolic, kodwa akukho ukuhlobana okuqondile okuboniswayo okukhonjisiwe. Ukukhubazeka kokusebenza kwesibindi kwakuyi-reaction engavamile kakhulu eholela ekuqedeni kwe-Uloric.
Kube khona imibiko yokuthunyelwa kwe-postmarketing yokuhluleka kwe-hepatic, engabulalayo futhi engabulali, kuziguli eziphathwe nge-Uloric. Imibiko yayingenayo idatha eyanele yokwakha imbangela engenzeka kodwa.
Ukwanda kwama-gout flares kuvame ukuhlangenwe nakho lapho ama-anti-hyperuricemic aqala khona. Lokho kubandakanya u-Uloric. Uma i-gout flare ehlobene nokuqaliswa kokwelashwa kwe-Uloric kwenzeka, isidakamizwa akudingeki sikhiyiwe. Ukuze uvimbele ama-gout flares ahlobene nokuqaliswa kokwelashwa kwe-Uloric, i- NSAID noma i-colchicine ingathathwa ngesikhathi esifanayo. Ukwanda kwama-gout flares kuye kwabhekwa ekunciphiseni amazinga e-serum uric acid, okubangela ukuthi ukunyakaza kwe-urate kusuka ekutheni i-deposit deposits.
Kubekho izifundo ezilawulwa kahle ze-Uloric kwabesifazane abakhulelwe. Ekukhulelweni, i-Uloric kufanele isetshenziswe kuphela uma inzuzo ekulindelwe iphakamisa ingozi engaba khona enganeni. Futhi, awaziwa ukuthi i-Uloric idonswa ubisi lomuntu.
Abesifazane abahlengikazi kumele baqaphe.
Ukuphepha nokusebenza kwe-Uloric ezinganeni ezingaphansi kweminyaka engu-18 ubudala aziwa.
Imithombo:
Ulwazi lokunyathelisa ulolu. Uloric.com. Takeda Pharmaceuticals Inc. Ukuhlaziywa ngoMashi 2013.
I-FDA ivumela ULORIC® (i-febuxostat) ye-Chronic Management of Hyperuricemia ezigulini ezine-Gout. Takeda Pharmaceuticals. Ngo-February 13, 2009.